Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Samsung, Quintiles Form Bio-Manufacturing JV | Contract Pharma

What are you searching for?

Sign in
Breaking News

Samsung, Quintiles Form Bio-Manufacturing JV

Samsung has formed a joint venture with Quintiles Transnational Corp., with $266 million of capital, in its first project in biopharmaceuticals.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Samsung has formed a joint venture with Quintiles Transnational Corp., with $266 million of capital, in its first project in biopharmaceuticals. The three Samsung companies partnering with Quintiles, which includes Samsung Electronics Co., will own 90% of the venture and Quintiles will own 10%.

Initially, a factory will be built in Incheon, South Korea to produce biopharmaceutical drugs to treat cancer and arthritis on a contract manufacturing basis. Construction will begin during 1H11, with production expected to begin during 1H13. The company plans to develop a biosimilar of Rituxan, according to a Bloomberg report. Samsung also has plans to develop new biopharmaceuticals as part of its comprehensive 10-year investment plan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters